Study
Multicenter, open-label, phase 1/2 trial |
Cisplatin ineligible local advanced/metastatic urothelial carcinoma |
Enfortumab vedotin +pembrolizumab q21 (n=45) |
Efficacy
CRR: 15.6% [7 of 45 pts] |
ORR: 73.3% [33 of 45 pts] |
mDOR: 25.6 mos [8.28-NR] |
mPFS: 12.3 mos [7.98-NR] |
mOS: 26.1 mos [15.74-NR] |
Safety
Grade3AEs: Lipase increased (17.8%), maculopapular rash (11.1%), fatigue (11.1%), peripheral sensory neuropathy (4.4%) |
J Clin Oncol 2023 41:1, 22-31
Enfortumab Vedotin Plus Pembrolizumab in Previously Untreated Advanced Urothelial Cancer
http://doi.org/10.1200/JCO.22.01643
Reviewed by Elvin Chalabiyev, MD on Apr 14, 2023